reports
- Sean Conroy
Creo - Unlocking the potential of rare cannabinoids
Private company Creo is a potential disrupter in the cannabinoids space, leveraging its proprietary bacterial fermentation technology to manufacture hitherto uneconomical rare cannabinoids at commercial scale. Initial focus is on cannabigerol (CBG), a non-psychoactive cannabinoid with potential application across the health, wellness and beauty industries. With its first commercial 28,000L manufacturing run achieved in August 2021 and collaboration agreements with Fifth & Root and Joiya announce...
- Sean Conroy
Creo - Unlocking the potential of rare cannabinoids
Private company Creo is a potential disrupter in the cannabinoids space, leveraging its proprietary bacterial fermentation technology to manufacture hitherto uneconomical rare cannabinoids at commercial scale. Initial focus is on cannabigerol (CBG), a non-psychoactive cannabinoid with potential application across the health, wellness and beauty industries. With its first commercial 28,000L manufacturing run achieved in August 2021 and collaboration agreements with Fifth & Root and Joiya announce...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.